Beyond Biology: Impact of Center- and Country-specific Economic Factors on Outcomes After Hematopoietic Cell Transplantation  by Khera, Nandita
EBioMedicine 2 (2015) 1869–1870
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comCommentaryBeyond Biology: Impact of Center- and Country-speciﬁc Economic
Factors on Outcomes After Hematopoietic Cell TransplantationNandita Khera
College of Medicine, Mayo Clinic, 5777 E Mayo Blvd, Phoenix, AZ 85054, United StatesDOI of original article: http://dx.doi.org/10.1016/j.ebi
http://dx.doi.org/10.1016/j.ebiom.2015.12.005
2352-3964/© 2015 The Author. Published by Elsevier B.Va r t i c l e i n f o characteristics are more common in afﬂuent countries and may explainArticle history:
Received 8 December 2015
Accepted 9 December 2015
Available online 12 December 2015
in part the better survival, decreased NRM and relapse risk after alloge-
neic HCT in countries with higher economic indices. However, the au-
thors rightly note that this relationship cannot be determined as
causal because of the nature of the study and analysis. The relationship
between outcomes and center- and country-speciﬁc factors is less de-Keywords:
Hematopoietic cell transplantationEver since the ﬁrst hematopoietic cell transplantation (HCT) was gree ofmedical complexity, risk and resource requirement. Even thoughperformed in 1960s, thousands of studies have elucidated the impact
of patient and donor factors (sociodemographic, disease and transplant
characteristics) on outcomes after the procedure. Fewer studies have
looked at the role of center speciﬁc factors such as procedure volume,
center experience or accreditation status in inﬂuencing the outcomes
(Loberiza et al., 2005; Horowitz et al., 1992; Gratwohl et al., 2014). Mac-
roeconomic factors such as gross national income per capita or health
care expenditure per capita have been shown to impact the diffusion
and utilization of HCT, because it is an expensive and resource intensive
technology (Gratwohl et al., 2013; Gratwohl et al., 2002). However, the
impact of these factors on outcomes hasn't been well studied especially
in the context of individual patient-level and center-speciﬁc factors.
In this issue of EBioMedicine, Baldomero et al. present a retrospec-
tive population level analysis that examines the interplay of patient-,
center- and country level factors on outcomes of allogeneic and autolo-
gous HCT using data from the European Society of Blood and Marrow
Transplantation (EBMT) database (Baldomero et al., 2015). The authors
use a large patient cohort with a long follow-up of 8 years from 404HCT
centers in 25 European countries and incorporate center- and country
speciﬁc economic data into a detailed multi-level analysis. They de-
scribe the association of program accreditation and duration, patient
volume, human development index, gross national income/capita, and
health care expenditures/capita with clinical outcomes (overall survival
(OS), non-relapse mortality (NRM) and relapse) after HCT while
adjusting for patient related factors. They report accreditation, higher
patient volumes and longer program duration as center properties
associated with better overall outcomes. These favorable centerom.2015.11.021.
. This is an open access article underﬁnitive in the case of autologous HCT.
The ﬁndings about the differential impact of macroeconomic factors
on survival after autologous and allogeneic HCT are novel, but not sur-
prising as these are two different types of procedures with different de-
the study is about HCT in Europe, it has wider implications. An impor-
tant question it raises is ‘if one size ﬁts all?’ for worldwide practice of
HCT or for that matter, any expensive medical technology. Should the
benchmarks for assessing the success of an expensive technology be
different amongst different countries at diverse stages of socioeconomic
development with different resource capacity (knowledge base, human
resources and institutional infrastructure)? The authors suggest
streamlining and consolidation of the transplant activity to help main-
tain the quality of care and strengthening the overall health infrastruc-
ture to provide optimal pre- and post-HCT care. This proposition and a
long term vision for the growth and sustainability of a transplant pro-
gram may be more important for the poorer countries than the richer
countries to help optimize the best utilization of the scarce resources.
This is because the spending on health care especially on high costmed-
ical technology is more likely to strain the government as well as indi-
vidual household budgets in poorer countries as opposed to afﬂuent
countries. The bigger question is if the poorer countries should spend
their limited resources to improve outcomes of expensive procedures
that beneﬁt only a few or focus on providing basic necessities and pre-
ventive care for a larger population?
The authors highlight the role of professional medical societies
worldwide in improving the quality of care and scaling up transplant
systems through education and training that ﬁt within the economic
framework of individual countries across the globe. This will need to
be supplemented with other measures such as international aid, advo-
cacy efforts, partnerships and investment in research in the afﬂuent
countries to develop affordable technologies. Bidirectional knowledge
transfer is important because the evolution of a technology devel-
oped in a richer country may follow a more cost-effective route
when implemented in developing countries. This may provide an op-
portunity for the afﬂuent countries to learn a less expensive way tothe CC BY license (http://creativecommons.org/licenses/by/4.0/).
1870 N. Khera / EBioMedicine 2 (2015) 1869–1870do things as long as it doesn't impact short- and long-term outcomes
(Ruiz-Delgado, 2012). Finally, the policy makers need to realize the im-
portance of bridging the divide between macroeconomic policy and
health policy to commit to building the necessary scientiﬁc and re-
search capacity that can optimally address the medical needs of the
country through careful resource allocation. We have crossed the one
millionmark for HCT across theworld, nowwe need to strive to achieve
a compromise between equity and efﬁciency.
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